Literature DB >> 11114377

CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling.

S Hida1, K Ogasawara, K Sato, M Abe, H Takayanagi, T Yokochi, T Sato, S Hirose, T Shirai, S Taki, T Taniguchi.   

Abstract

The balanced action of cytokines is known to be critical for the maintenance of homeostatic immune responses. Here, we report the development of an inflammatory skin disease involving CD8(+) T cells, in mice lacking the transcription factor, interferon regulatory factor-2 (IRF-2). CD8(+) T cells exhibit in vitro hyper-responsiveness to antigen stimulation, accompanied with a notable upregulation of the expression of genes induced by interferon-alpha/beta (IFN-alpha/beta). Furthermore, both disease development and CD8(+) T cell abnormality are suppressed by the introduction of nullizygosity to the genes that positively regulate the IFN-alpha/beta signaling pathway. IRF-2 may represent a unique negative regulator, attenuating IFN-alpha/beta-induced gene transcription, which is necessary for balancing the beneficial and harmful effects of IFN-alpha/beta signaling in the immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114377     DOI: 10.1016/s1074-7613(00)00064-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  76 in total

1.  Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2.

Authors:  Eri Ichikawa; Shigeaki Hida; Yoshiki Omatsu; Susumu Shimoyama; Kazuhiko Takahara; Shinichi Miyagawa; Kayo Inaba; Shinsuke Taki
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-02       Impact factor: 11.205

2.  Negative regulation of IFN-alpha/beta signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells.

Authors:  Kenya Honda; Tatsuaki Mizutani; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 3.  Transcriptional programming of the dendritic cell network.

Authors:  Gabrielle T Belz; Stephen L Nutt
Journal:  Nat Rev Immunol       Date:  2012-01-25       Impact factor: 53.106

Review 4.  Regulation of T helper cell differentiation by interferon regulatory factor family members.

Authors:  Ruihua Zhang; Kang Chen; Liang Peng; Huabao Xiong
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 5.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

Review 6.  Janus-like effects of type I interferon in autoimmune diseases.

Authors:  Robert C Axtell; Chander Raman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 7.  Mechanisms of self-renewal in hematopoietic stem cells.

Authors:  Zhao Wang; Hideo Ema
Journal:  Int J Hematol       Date:  2015-12-12       Impact factor: 2.490

8.  Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury.

Authors:  Ling-Juan Zhang; George L Sen; Nicole L Ward; Andrew Johnston; Kimberly Chun; Yifang Chen; Christopher Adase; James A Sanford; Nina Gao; Melanie Chensee; Emi Sato; Yi Fritz; Jaymie Baliwag; Michael R Williams; Tissa Hata; Richard L Gallo
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

9.  Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2).

Authors:  Quan M Nhu; Natalia Cuesta; Stefanie N Vogel
Journal:  J Endotoxin Res       Date:  2006

10.  PRDM16 represses the type I interferon response in adipocytes to promote mitochondrial and thermogenic programing.

Authors:  Megan Kissig; Jeff Ishibashi; Matthew J Harms; Hee-Woong Lim; Rachel R Stine; Kyoung-Jae Won; Patrick Seale
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.